(Q48297628)

10 February 2018

title

Multiple sclerosis: oral BG12 for treatment of relapsing-remitting MS. (English)

1 reference

10 February 2018

0 references

Volker Limmroth

1

1 reference

10 February 2018

language of work or name

English

0 references

publication date

13 November 2012

1 reference

10 February 2018

published in

Nature Reviews Neurology

1 reference

10 February 2018

volume

9

1 reference

10 February 2018

issue

1

1 reference

10 February 2018

page(s)

8-10

1 reference

10 February 2018

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.231

1 reference

Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.231

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.231

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.231

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2012.231

[Treatment of psoriasis vulgaris.]

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23147843

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRNEUROL.2012.231

1 reference

10 February 2018

1 reference

10 February 2018